Effect of Maintaining Highly Active Antiretroviral Therapy on AIDS Events among Patients with Late-Stage HIV Infection and Inadequate Response to Therapy
Open Access
- 15 March 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (6) , 878-884
- https://doi.org/10.1086/500210
Abstract
Background. We evaluated the effect of maintaining highly active antiretroviral therapy (HAART) on the development of new acquired immunodeficiency syndrome (AIDS)-related events in patients with late-stage human immunodeficiency virus (HIV) infection who had suboptimal CD4+ cell count and viral load responses to HIV therapy. Methods. In patients with pretreatment CD4+ cell counts of 3, incidence rates of new AIDS-related events occurring during HIV treatment were calculated during period 1 (pre-HAART era, 1990–1995; 88 patients) and period 2 (HAART era, 1996–2004; 214 patients) according to CD4+ cell count responses while receiving treatment. Cox multivariate model was used to compare rates of AIDS-related events from period 2 with those from period 1 according to specific CD4+ cell count response categories and rates of AIDS-related events for various viral load ranges within CD4+ cell count categories during period 2. Results. For period 2 patients with CD4+ cell counts 100,000 copies/mL, the rate of AIDS-related events (39.3 events per 100 person-years) was significantly lower than that for period 1 patients with CD4+ cell counts 3 (76.4 events per 100 person-years; P = .02). This held true for patients with CD4+ cell counts 100,000 copies/mL (29.5 events per 100 person-years; P = .01). Similarly, for patients with CD4+ cell counts of 100–200 cells/mm3, there were fewer AIDS-related events in period 2 (7.8 events per 100 person-years) than in period 1 (34.5 events per 100 person-years; P = .001); even for patients in period 2 with viral loads >100,000 copies/mL (15.4 events per 100 person-years; P = .04). Conclusions. Our data suggest that, even among patients with late-stage HIV infection and inadequate CD4+ cell count and viral load responses to HIV therapy, maintaining HAART may reduce the incidence of AIDS-related events.Keywords
This publication has 16 references indexed in Scilit:
- Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell CountJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Improved Outcomes with Earlier Initiation of Highly Active Antiretroviral Therapy Among Human Immunodeficiency Virus–Infected Patients Who Achieve Durable Virologic Suppression: Longer Follow‐Up of an Observational Cohort StudyThe Journal of Infectious Diseases, 2003
- CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 YearsThe Swiss HIV Cohort StudyArchives of internal medicine (1960), 2003
- Mortality and progression to AIDS after starting highly active antiretroviral therapyAIDS, 2003
- Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency VirusNew England Journal of Medicine, 2003
- Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studiesThe Lancet, 2003
- Immune Reconstitution Inflammatory SyndromeMedicine, 2002
- High Levels of Drug‐Resistant Human Immunodeficiency Virus Variants in Patients Exhibiting Increasing CD4+T Cell Counts Despite Virologic Failure of Protease Inhibitor–Containing Antiretroviral Combination TherapyThe Journal of Infectious Diseases, 2000
- AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral TherapyJAMA, 1999
- The Incidence of AIDS-Defining Illnesses in 4883 Patients With Human Immunodeficiency Virus InfectionArchives of internal medicine (1960), 1998